Yizun Biopharmaceutical

Yizun Biopharmaceutical (Zhejiang) Co., Ltd. is a clinical-stage biopharmaceutical entity established in 2018, concentrating on the development of cell therapies for solid tumors. The company was co-founded by Dr. Liu Lingfeng, an expert in immunotherapy, and Mr. Guo Xiaobin, who contributes extensive experience in investment and innovation incubation. Dr. Liu's background includes direct participation in CAR-T cell therapy development and clinical research at the Fred Hutchinson Cancer Research Center in the U.S., where he secured several international patents, some of which were licensed to Juno Therapeutics.

The company's core business revolves around the research and development of treatments for solid tumors and allogeneic cells, with a specific focus on accelerating the creation of allogeneic cell drugs for advanced liver cancer. Yizun Biopharmaceutical operates on a model that involves developing proprietary technology platforms and advancing product pipelines through clinical trials. It has established three primary technology platforms: CNK-T, VAC-T, and UT. The CNK-UT platform, in particular, demonstrated initial clinical efficacy in treating liver cancer in July 2020.

Revenue generation is intrinsically tied to the successful development and subsequent commercialization or licensing of its therapeutic products. The company has secured significant funding to support its operations, including a Pre-A round in June 2019 from Livzon Pharm, a Series A round in January 2022 co-led by VMS and Shenzhen Capital, and a Series A1 round in April 2024. These funds are allocated towards talent acquisition, R&D, clinical trials, and optimizing its technology platforms. To facilitate its research and production, the company operates a nearly 3,000-square-meter GMP production workshop and clinical transformation center in Hangzhou.

Keywords: cell therapy, solid tumors, immunotherapy, allogeneic cells, biopharmaceutical, oncology, liver cancer treatment, CAR-T, clinical trials, drug development, biotechnology, CNK-T, VAC-T, UT platform, GMP manufacturing, Zhejiang, Hangzhou, Dr. Liu Lingfeng, Guo Xiaobin, venture capital-backed